# US 2023/0266336 A1 · Coronavirus Assays, Diagnostic Methods, Treatment Methods, and Compositions Related Thereto

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0266336 A1
- Document ID: US20230266336A1
- Status: Published application
- Kind: A1
- Application number: 17/922,670
- Filed: 2021-05-03
- Published: 2023-08-24
- Earliest claimed: 2020-05-01
- Assignees: Emory University
- Applicants: Emory University
- Inventors: Rafi Ahmed; Mehul Suthar; Jens Wrammert; John Roback; Robert Kauffman
- Web page: https://patentgrep.com/patent/US20230266336A1

## CPC

- A61K 39/12: Viral antigens
- G01N 33/6854: {Immunoglobulins}
- G01N 33/54386: {Analytical elements}
- G01N 33/56983: {Viruses}
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This disclosure relates to coronavirus assays, diagnostic methods, treatment methods, and compositions related thereto. In certain embodiments, this disclosure relates to ACE2 receptor binding domain peptides and uses in serological assays and vaccination methods.

## Claims

### Claim 1

A peptide comprising
SEQ ID NO: 1 (MFVFLVLLPLVSRVQPTESIVRFPNITNLCPFGEVF
NATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCF
TNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLD
SKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPL
QSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF)
or variant thereof with greater than 80% identity, wherein SEQ ID NO: 1 comprises a polyglycine and a polyhistidine on the C-terminus.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The peptide of claim 1 wherein a serine amino acid is between the polyglycine and the polyhistidine.

### Claim 4

A peptide consisting of
SEQ ID NO: 2 (MFVFLVLLPLVSRVQPTESIVRFPNITNLCPFGEVF
NATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCF
TNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLD
SKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPL
QSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFG
GGGSHHHHHH).

### Claim 5 (depends on 4)

The [A] peptide of claim 4 conjugated to or coated on a solid surface, a particle, magnetic particle, or a fluorescent particle.

### Claim 6 (depends on 4)

The [A] peptide of claim 4 conjugated to a fluorescent dye, radioisotope, or enzymatic label.

### Claim 7 (depends on 4)

A nucleic acid or vector encoding the [a] peptide of claim 4 in operable combination with a heterologous promotor.

### Claim 8 (depends on 7)

An expression system or cell comprising the [a] nucleic acid or vector of claim 7.

### Claim 9 (depends on 4)

A method of detecting coronavirus antibodies in a subject comprising
contacting a sample from a subject containing a coronavirus antibody that specifically binds an ACE2 receptor binding domain with a peptide of claim 4; and
detecting binding of the antibody to the peptide thereby detecting a coronavirus antibody in the sample of the subject.

### Claim 10 (depends on 9)

The method of claim 9, wherein the subject is at risk of, exhibiting symptoms of, or diagnosed with a SARS-CoV-2 infection.

### Claim 11 (depends on 4)

A method of detecting a coronavirus antibody comprising
providing a solid surface coated with a peptide of claim 4;
contacting the solid surface with a sample from a subject suspected of having a coronavirus infection; wherein if the sample comprises an antibody that binds an expose epitope of the peptide, then a complex of the peptide and subject derived antibody is formed;
contacting the complex with an immunoglobulin specific antibody conjugated to a label providing a second complex of a labeled immunoglobulin antibody and the subject derived antibody;
detecting the second complex of a labeled immunoglobulin antibody and the subject derived antibody thereby detecting a coronavirus antibody in the sample of the subject.

### Claim 12

(canceled)

### Claim 13 (depends on 4)

A pharmaceutical composition comprising a peptide of claim 4 and a pharmaceutically acceptable excipient.

### Claim 14 (depends on 4)

A vaccination method comprising administering an effective amount of a peptide of claim 4 to a subject optionally in combination with an adjuvant.

### Claim 15

(canceled)
